Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
BioAge Stock Rallies 29% Following Upsized $198M IPO
Oppenheimer points out the next "trend" for weight loss drugs: oral over-the-counter medication.
The competition to develop oral weight-loss drugs is intensifying.
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Eli Lilly Unusual Options Activity
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Novo Nordisk, Lilly Weight Loss Drugs Poised for Price Reductions: Cantor's Louise Chen
Lilly Ebglyss Demonstrates Durable Disease Control in Atopic Dermatitis
Express News | New Data Show Lilly's Ebglyss™ (Lebrikizumab-Lbkz) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
New Data Show Lilly's EBGLYSS (Lebrikizumab-lbkz) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
US stocks closed: S&P, Dow hit new highs again. Chinese concept stocks staged a 'Golden Dragon Soaring'.
1. The three major indices collectively rose, with the S&P 500 index and the Dow hitting new highs; 2. Chinese concept stocks generally soared, with the Nasdaq Golden Dragon Index in China rising by 9.13%; 3. Nvidia rose by about 4%, temporarily halting the selloff by Huang Renxun; 4. The US Department of Justice sued Visa, accusing it of illegal monopolization.
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
Roche Narrows Pipeline to 11 Disease Areas Amidst Weight Loss Push - WSJ
Novo CEO Faces Sen. Sanders in Drug Price Showdown -- Barrons.com
Novo Nordisk CEO Set to Defend Ozempic, Wegovy Prices on Capitol Hill